Hong S P, Park J Y, Jeon T J, Bang S, Park S W, Chung J B, Park M-S, Seong J, Lee W J, Song S Y
Division of Gastroenterology, Department of Internal Medicine, Yonsei Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
Br J Cancer. 2008 Mar 11;98(5):881-7. doi: 10.1038/sj.bjc.6604247. Epub 2008 Feb 26.
The aim of this study was to evaluate the efficacy and the toxicity of a full dose of gemcitabine and a single dose of cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer. Forty-one patients with locally advanced pancreatic cancer were enrolled. Patients received gemcitabine (1000 mg m(-2) on days 1, 8, 15, 29, and 36) and cisplatin (70 mg m(-2) on days 1 and 29) with concurrent radiotherapy (45 Gy in 25 fractions). Treatment was completed in 38 out of 41 patients (92.7%). The overall response rate was 24.4% (two complete and eight partial). Six patients (14.6%) underwent definite pancreatic resection and four had negative surgical margins. The intention of the treatment analysis showed that the median survival time and median time to tumour progression were 16.7 and 8.9 months. The 1- and 2-year survival rates were 63.3 and 27.9%, respectively. Overall survival was significantly longer in the low baseline CA19-9 group and therapeutic responders. Toxicities were tolerable and successfully managed by conservative treatments. The therapeutic scheme of a weekly full dose of gemcitabine and a single dose of cisplatin combined with external radiation is effective and might prolong the survival of patients with locally advanced pancreatic cancer.
本研究旨在评估全剂量吉西他滨和单剂量顺铂同步放疗对局部晚期胰腺癌患者的疗效和毒性。纳入41例局部晚期胰腺癌患者。患者接受吉西他滨（第1、8、15、29和36天，1000 mg/m²）和顺铂（第1和29天，70 mg/m²）同步放疗（25次分割，45 Gy）。41例患者中有38例（92.7%）完成治疗。总缓解率为24.4%（2例完全缓解，8例部分缓解）。6例患者（14.6%）接受了确定性胰腺切除术，4例手术切缘阴性。意向性治疗分析显示，中位生存时间和中位肿瘤进展时间分别为16.7个月和8.9个月。1年和2年生存率分别为63.3%和27.9%。低基线CA19-9组和治疗反应者的总生存期明显更长。毒性反应可耐受，通过保守治疗成功处理。每周全剂量吉西他滨和单剂量顺铂联合外照射的治疗方案有效，可能延长局部晚期胰腺癌患者的生存期。
